Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Sophiris reports patient death in prostate cancer trial

Chris Lieu
June 29, 2018 2:54 PM UTC

Sophiris Bio Inc. (NASDAQ:SPHS) reported a patient death in an open-label, U.S. and U.K. Phase IIb trial evaluating topsalysin (PRX302) to treat localized prostate cancer.

The company said it is evaluating the cause of death. The event occurred on the same day the patient received a second intraprostatic administration of topsalysin. The candidate is a recombinant proaerolysin protein activated by prostate-specific antigen (PSA; KLK3)...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Sophiris Bio Inc.